Quarterly report pursuant to Section 13 or 15(d)

Loans Receivable - Components (Details)

v3.24.1.1.u2
Loans Receivable - Components (Details) - USD ($)
 1 Months Ended 3 Months Ended
Sep. 30, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Aug. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable   $ 8,932,000   $ 8,968,000  
Less allowance for expected credit losses   (7,902,000)   (7,902,000)  
Loans receivable   1,030,000   1,066,000  
Additional allowance for credit losses   0      
Teneo Fund SPVi LLC note          
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable   5,586,000   5,622,000  
Pharma EU, LLC note          
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable   1,410,000   1,410,000  
A&R note          
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable   710,000   710,000  
SSZ and Elev8 note          
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable   1,002,000   1,002,000  
Pure Hana Synergy note          
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable   224,000   $ 224,000  
Little Beach Harvest Note          
Accounts, Notes, Loans and Financing Receivable [Line Items]          
Total loans receivable $ 0        
Interest and Fee Income, Loans and Leases   $ 0 $ 64,000    
Write off of loan receivable including both principal and accrued interest $ 5,135,000        
Interest rate on loans receivable         9.00%